332 studies on GLP-1R mechanism curated from PubMed, ClinicalTrials.gov, and EuropePMC. Updated daily.
This case report carries significant clinical implications, particularly for endocrinologists and primary care providers prescribing tirzepatide to patients with complex endocrine histories. The finding underscores th…
Optimizing Survodutide's formulation is critical for its future development as a potential treatment for obesity and NASH. A formulation with improved bioavailability could lead to more effective dosing strategies, po…
Understanding Liraglutide's direct effects on inflammation could significantly broaden its therapeutic implications beyond glycemic control and weight management. If Liraglutide can effectively reduce adipose tissue i…
If liraglutide were found to be effective and safe as an add-on therapy for Type 1 Diabetes, it could represent a significant advancement in managing this complex condition. Such a finding could potentially lead to im…
Identifying predictive biomarkers for Liraglutide response could revolutionize obesity treatment by enabling personalized medicine. If successful, this research could allow clinicians to prescribe Saxenda® more effect…
Understanding how age affects Liraglutide's pharmacokinetics is crucial for optimizing treatment strategies, especially given the increasing prevalence of type 2 diabetes and obesity in the elderly population. If sign…
While this specific study did not yield results, the underlying hypothesis of combining GLP-1 agonists with increased Non-exercise Activity Thermogenesis (NEAT) remains highly relevant for optimizing Type 2 Diabetes m…
The concept behind this trial was significant: liraglutide, a GLP-1 receptor agonist, has shown potential in preserving beta-cell function and promoting their survival, which could theoretically enhance the success an…
The successful completion of the REDEFINE 3 trial could have a profound impact on the management of cardiovascular disease, particularly in patients who may also have metabolic comorbidities. If CagriSema demonstrates…
If the anticipated results confirm strong efficacy and a favorable safety profile, CagriSema could represent a significant advancement in the pharmacological treatment of obesity. By combining two distinct yet complem…
Oral semaglutide represents a significant advancement in Type 2 Diabetes management, offering a convenient oral alternative to injectable GLP-1 receptor agonists. Real-world studies like this are vital because they pr…
If successful, this Phase 3 trial could introduce a new, potentially effective treatment option for Type 2 Diabetes patients who require additional glycemic control beyond oral medications. A positive outcome could le…
The daily burden of carbohydrate counting remains a significant challenge for individuals with Type 1 Diabetes, even with the most advanced closed-loop systems. If weekly Semaglutide proves effective in reducing this …
This research is crucial for identifying cognitive-behavioral markers that predict successful long-term weight loss following bariatric surgery or liraglutide treatment. Understanding these markers could lead to more …
This case report highlights a critical safety concern, suggesting that clinicians should exercise extreme caution when reinitiating GLP-1 receptor agonists like semaglutide after a treatment break. The key implication…
As an active Phase 3 study with an estimated completion date of June 2026, specific efficacy and safety results comparing IBI362 and Semaglutide are not yet available. The study is designed to assess the non-inferiori…
The successful completion of this Phase 1/2 study marks a critical developmental milestone for IBI362 as a potential therapeutic agent for overweight and obesity. Establishing the initial safety profile and understand…
This completed Phase 4 clinical trial represents a significant step towards optimizing care for morbidly obese patients undergoing bariatric surgery. If the results, once published, demonstrate improved preoperative h…
The co-administration of Cagrilintide and Semaglutide represents a potentially significant advancement in the treatment paradigm for Type 2 diabetes. Semaglutide is a GLP-1 receptor agonist known for its glucose-lower…
Effective management of Type 2 Diabetes often requires combination therapies to achieve optimal glycemic control and address comorbidities like obesity. CagriSema combines semaglutide (a potent GLP-1 receptor agonist)…
Understanding semaglutide's direct neurological effects in healthy individuals is profoundly important for expanding its therapeutic potential. If this study reveals positive acute cognitive or energy-enhancing effect…
The successful demonstration of feasibility and tolerability could open new avenues for managing obesity in patients with advanced lung disease, potentially improving their quality of life and clinical outcomes. If Se…
Reducing injection site pain is a critical factor for improving patient adherence to long-term therapies like Semaglutide, which is often administered weekly for chronic conditions such as Type 2 Diabetes and Obesity.…
This regulatory post-marketing surveillance study is crucial for gathering real-world evidence on oral semaglutide, complementing data from controlled clinical trials. Such data is vital for understanding how the drug…
This Phase 2 trial is crucial as it explores a novel combination therapy that could significantly advance the treatment landscape for obesity and Type 2 Diabetes. If successful, combining LY3841136 with Tirzepatide co…
This study addresses a critical unmet need for patients with psoriatic arthritis who also struggle with obesity, a common comorbidity that complicates disease management and often reduces the effectiveness of existing…
Understanding the effects of GLP-1 agonist discontinuation is crucial for informing patient care and developing strategies to manage potential rebound effects and improve long-term outcomes. Many patients may need to …
This comprehensive review provides a critical, evidence-based framework for clinicians managing Type 2 Diabetes, moving beyond a glucose-centric approach. It underscores the importance of personalized medicine, where …
While this specific study was terminated without reporting results, the underlying research question remains highly relevant. If completed, positive findings could have highlighted Liraglutide's potential beyond weigh…
If IBI362 demonstrates superior or comparable efficacy with a favorable safety profile against dulaglutide, it could represent a significant advancement in Type 2 Diabetes management. This would provide a new therapeu…
This large-scale registry is crucial for understanding the current state of obesity and Type 2 Diabetes Mellitus management in China, a region with unique dietary and lifestyle factors. The real-world data collected w…
The successful completion of this Phase III trial could establish IBI362 as a novel and effective treatment option for MAFLD, a condition with limited approved pharmacotherapies. Given the high prevalence of MAFLD in …
This Phase 1 study is crucial for the continued development of survodutide, as it provides foundational data on how the drug behaves in a specific ethnic population. Understanding the pharmacokinetics and safety profi…
While this specific study did not yield data, the initial intent highlights a critical area of need: understanding how combination therapies like IDegLira perform in real-world settings for patients whose Type 2 Diabe…
The abstract outlines the study's primary objective to determine the effectiveness and safety of adding GLP-1 agonist therapy to basal insulin. The investigators hypothesized that this combination would lead to statis…
This study provides strong evidence supporting the enhanced efficacy of combining a basal insulin (insulin degludec) with a GLP-1 receptor agonist (liraglutide, a class of drugs that mimic a natural hormone to lower b…
As this PHASE 4 clinical trial is currently RECRUITING participants, specific findings are not yet available, with an estimated completion date of 2026-07-01. Researchers are meticulously collecting data from an estim…
Tirzepatide has already demonstrated significant efficacy, and exploring higher or alternative dosing strategies could further optimize patient outcomes by potentially enhancing glycemic control and weight loss. This …
The successful completion of this Phase 3 trial is a significant milestone, as Tirzepatide (a dual GIP and GLP-1 receptor agonist) has already demonstrated robust efficacy in adults with Type 2 Diabetes and obesity. I…
The first approval of Mazdutide in China is a pivotal development, introducing a novel dual glucagon receptor (GcgR) and glucagon-like peptide-1 receptor (GLP-1R) agonist to the therapeutic landscape. This provides a …